• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information


Clinical settingPatients with referred for PET to find an unidentified primary tumour. Prior to PET. all patients had a physical examinaton, blood chemistry, liver ultrasound, and presentation dependent tests (breast US, mammography, CT, MRI, cervical US, and panendoscopy).
Participants and Country24 patients. Belguim
Study designRetrospective case series.
Target conditionTo identify the location of the primary tumour. Reference standard was biopsy (in cases where therapuetic or palliative benefit was expected) or further imaging.
TestsFDG-PET, Seimens ECAT EXACT. 370 MBq FDG
Follow upAt least six months.
Study TypeI
PET imaging fieldWhole body
Biopsy of metastasisHistology of metastasis was known in 22/24 patients. Adenocarcinoma (18/22), squamous cell carcinoma (2/22) and poorly differentiated carcinoma (2/22).

From: Guideline chapter 2, Diagnosis

Cover of Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin
Diagnosis and Management of Metastatic Malignant Disease of Unknown Primary Origin.
NICE Clinical Guidelines, No. 104.
National Collaborating Centre for Cancer (UK).
Copyright © 2010, National Collaborating Centre for Cancer.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licenses issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.